Thermo Fisher Scientific Beats Q3 by 2 Points of Organic Growth as Pharma Services Pulls Forward; $0.15 of EPS Upside Came from One-Time Tariff Refunds
Q3 2026 earnings call, October 21, 2026: guidance raised, but the quality of the beat needs unpacking
Thermo Fisher Scientific reported third quarter revenue of $12.14 billion, up 9%, with organic growth of 6%. Adjusted EPS rose 15% to $6.68. Revenue came in more than $200 million ahead of prior guidance, including roughly 2 points of better organic growth and some foreign exchange help. Adjusted EPS was $0.26 above guidance. The composition of that EPS beat matters for investors: only $0.08 came from operations, including pull-through on stronger revenue, and $0.03 from currency. The remaining $0.15 was the net benefit of tariff refunds that were not in prior guidance.
Tariff refunds flatter the margin, and part was reinvested
CFO Jim Meyer said the company received approvals and recognized recoveries on "the vast majority" of its potential refund claims in the quarter. The net impact was about $60 million of adjusted operating income, or 50 basis points of margin, with negligible revenue effect. Adjusted operating income grew 15% to $2.97 billion and margin expanded 120 basis points to 24.5%, so roughly 40% of the year-over-year margin gain traces to a nonrecurring item. Adjusted gross margin was 42.8% and adjusted SG&A was 15.5% of revenue.
Management said the figure is net of reinvestment, including faster AI deployment, added capacity in pharma services and additional spending on employees. Meyer said the one-time nature of the refunds "provided us a unique opportunity to make incremental short-term investments." About $40 million more will be reinvested in the fourth quarter. The full-year guide still assumes 80 basis points of adjusted operating margin expansion.
Pharma services timing explains the Q3 strength and the flat Q4 guide
The quarter's upside was concentrated in pharma services. In response to a question from Operon Research's Jack Meehan on why the fourth quarter guide of 4% organic growth was held after a 6% third quarter, Meyer pointed to timing. "There is some customer activity timing that was completed in the third quarter, but we're fully offsetting that with the momentum of the business in the fourth quarter to maintain our guidance." He said pharma services is the main driver of the sequential step down from 6% to 4%, even though the fourth quarter has an extra selling day.
Thermo Fisher now expects second-half organic growth of about 5%, compared with a prior 4% outlook and 3% in the first half. Full-year organic growth is now 4%, versus 2% in 2025. Revenue guidance rises to $47.7 billion to $48.2 billion, or 7% to 8% reported growth. Adjusted EPS guidance moves to $25.13 to $25.43, up 10% to 11%. The midpoint increase of $0.15 comprises $0.09 from operations, $0.05 from net tariff recovery and $0.01 from FX. Free cash flow guidance rises to $7.0 billion to $7.5 billion. Operations therefore account for less than two-thirds of the EPS raise.
End markets: biotech recovery is sequencing, with high-end reagents still lagging
CEO Marc Casper said the improved end market conditions first seen in the second quarter continued. Pharma and biotech grew high single digits, led by pharma services and the research and safety market channel, with strong clinical research growth. Industrial and applied also grew high single digits, driven by electron microscopy demand from semiconductor customers. Academic and government was flat, which management said was as expected, and diagnostics and healthcare grew low single digits.
Casper laid out the biotech recovery in stages, which is useful for judging where the cycle stands. Clinical research authorizations recovered first and have converted into revenue. Laboratory activity through the research and safety channel followed. High-tech life science research reagents are the next step, and Casper said they were "fairly similar to what we saw in Q2." He expects customers to spend more on these over the next couple of quarters. This is not yet visible in results. Life Sciences Solutions grew only 1% organically, and Casper acknowledged "a more muted environment" for bioscience and genetic science reagents.
Bioproduction was the segment's strongest business but decelerated against tough comparisons. Casper described growth as "a little bit less than what we had in the last quite a number of quarters" and reiterated a long-term profile of high single digit to low double digit growth. Segment margin was 37.6%, up 20 basis points, with productivity partly offset by mix and the dilution from the filtration and separation acquisition.
Segment and regional detail
Analytical Instruments was the standout, with 6% organic growth, adjusted operating income up 26% and margin up 430 basis points to 26.9% on productivity, volume leverage and favorable mix. Electron microscopy was very strong and chromatography and mass spectrometry was good. Laboratory Products and Biopharma Services grew 10% organically and 15% reported, with margin up 100 basis points to 15.5%, helped by Clario. Specialty Diagnostics was flat organically and down 6% reported on the microbiology divestiture, but margin rose 360 basis points to 31.0%.
Geographically, North America and Europe grew mid-single digits. Asia Pacific grew low double digits, and China did as well, improving sequentially, led by pharma, biotech and industrial and applied. Solventum's purification and filtration business has now passed its first anniversary, and Meyer said it remains on track as a mid to high single-digit grower with investment in capacity and strong customer adoption.
AI: bullish framing, no quantification yet
AI dominated the analyst questions, but management offered little in the way of numbers. Casper cited embedded AI on the Krios 5 and Glacios 3 cryo-electron microscopes, which cuts manual setup time by about 90%, and a new agentic clinical research assistant built on proprietary clinical and operational data. The company opened its first AI-Automation Innovation Center in South Korea, chosen because the government rewards researchers for adopting AI.
On the demand argument, Casper said that "the more that AI enables better medicines for unmet needs, the brighter the future is," pointing to COVID vaccines and GLP-1s as proof of how large end markets can become. He called the 7% organic growth target for a "truly normal" environment "not the cap on it." Asked by TD Cowen's Dan Brennan whether AI could add 1 to 2 points, Casper declined to size it. He said guidance on February 2 will touch on AI and that a "Chapter 2" investor day would address quantification. Investors hoping for a raised long-term algorithm should not expect one before then.
2027 framing: a gradual path, no promise of timing
Casper would not preview 2027 guidance, which comes February 2 at 8:30 a.m. He framed the path as 2% growth in 2025, 4% in 2026 with a stronger second half, and a goal of exiting 2027 in a normal growth environment. On timing he was candid: "I'm not smart enough to know exactly which quarter... I don't think anybody is that smart." He mentioned the back half of 2027 or first half of 2028 as possible windows. That suggests a gradual reacceleration rather than a sharp rebound in 2027.
Balance sheet, capital deployment and modeling items
Year-to-date free cash flow was $4.6 billion after $1.2 billion of net capital expenditures. In the quarter, Thermo Fisher repaid about $1.1 billion of senior notes, paid $175 million of dividends and received $1 billion from the microbiology sale. Total debt was $41.4 billion against $6.1 billion of cash. Leverage was 3.4x gross and 2.9x net debt to adjusted EBITDA, and adjusted ROIC was 11%. That level of leverage and ROIC reflects the cost of the Clario and filtration deals, which management said are performing well, with Clario integration "going smoothly" and revenue synergies building.
Full-year assumptions include net interest expense of about $650 million, an adjusted tax rate of 11.5% (11.6% in Q3), net capital expenditures of $1.9 billion to $2.0 billion, $4 billion of buybacks already completed and about $700 million of dividends. The diluted share count is expected at 371 million to 372 million. R&D was $350 million in the quarter, or 6.7% of manufacturing revenue.